S-1/A: Kestra Medical Technologies Eyes $150 Million in Nasdaq IPO

Kestra Medical Technologies, a wearable medical device company, is seeking to raise capital through an initial public offering of 10 million common shares, with an expected price range of $14 to $16 per share.

Summary

• Kestra Medical Technologies is planning an initial public offering (IPO) to sell 10,000,000 common shares.
• The expected price range for the shares is between $14.00 and $16.00 each.
• The company has applied to list its common shares on The Nasdaq Global Select Market under the ticker symbol KMTS.
• Post-IPO, an investment fund advised by Bain Capital, L.P. is expected to own approximately 52.8% of Kestra's common shares (or 51.2% if underwriters fully exercise their over-allotment option).
• Kestra is identified as an emerging growth company and a smaller reporting company, which allows it to comply with reduced public company reporting requirements.
• The underwriters have a 30-day option to purchase up to 1,500,000 additional common shares.
• Up to 5% of the offered common shares are reserved for sale to Kestra's officers, directors, team members, and their friends or family through a reserved shares program.
• Kestra intends to use the net proceeds from the IPO to scale up its commercial organization, fund research and development, and for working capital and general corporate purposes.
• Preliminary estimated revenue for the three months ended January 31, 2025 is expected to be between $14.5 million and $15.5 million, representing a 75% to 87% increase compared to the same period in 2024.
• The company anticipates a gross margin between 42.6% and 43.5% for the three months ended January 31, 2025.
• Kestra expects a loss from operations between $20.4 million and $20.8 million for the three months ended January 31, 2025.
• As of January 31, 2025, Kestra estimates having approximately $54.4 million in cash and cash equivalents and $43.7 million in net long-term debt.

Sentiment

Score: 7

Explanation: The document presents a balanced view, highlighting both the company's growth potential and the risks associated with its business. The positive aspects, such as the innovative technology and strong market opportunity, are tempered by the challenges of achieving profitability and managing competition.

Positives

• Kestra's Cardiac Recovery System platform offers a comprehensive solution for cardiac patients at risk of sudden cardiac arrest.
• The ASSURE WCD has demonstrated clinical advantages, including greater patient compliance and a low false alarm rate.
• The company is experiencing rapid revenue growth, with a 190% increase in the six months ended October 31, 2024, compared to the same period in 2023.
• Kestra has established reimbursement and favorable payor coverage for its ASSURE WCD.
• The company has a strong and compelling body of clinical evidence supporting the safety and efficacy of its ASSURE WCD.
• The company has made material investments in infrastructure to support rapid growth and scale.

Negatives

• Kestra has a limited operating history, which may make it difficult to evaluate its current business and its likelihood of success and viability.
• The company has a history of net losses, and there is no assurance as to when it will achieve profitability.
• Kestra's recurring losses from operations and financial condition raise substantial doubt about its ability to continue as a going concern.
• The company is dependent on a limited number of third-party suppliers and contract manufacturers to manufacture and recondition its ASSURE WCD and its components, which could make it vulnerable to supply shortages and price fluctuations that could harm its business.
• The company has identified material weaknesses in its internal control over financial reporting, and may identify additional material weaknesses.

Risks

• The company faces competition from ZOLL Medical Corporation, its primary competitor, and potential new market entrants.
• The estimates of Kestra's market and forecasts of market growth included in the prospectus are based on a number of complex assumptions and estimates that may prove to be inaccurate.
• The company's commercial success depends in part on the extent to which governmental authorities and health insurers provide coverage and adequate reimbursement levels.
• Bain Capital controls Kestra, and its interests may conflict with those of other shareholders.
• The market price of Kestra's common shares may be volatile, and investors may be unable to resell their shares at or above the initial public offering price.

Future Outlook

The company expects to continue incurring losses for the next several years and there is no assurance as to when it will achieve profitability, if at all, or whether it will be able to maintain profitability, if achieved, in the future.

Management Comments

• The ASSURE WCD was purpose-built to enhance patient comfort and compliance and directly address the key barriers to adoption associated with the only other commercially available WCD.
• We believe our Cardiac Recovery System platform addresses serious unmet needs in the cardiac patient population and has the potential to disrupt and grow the market which has been limited to a single solution for more than 20 years.

Industry Context

The WCD market has been dominated by a single player for over 20 years. Kestra is positioning itself as a disruptor with a next-generation device and comprehensive digital health platform.

Comparison to Industry Standards

• The ASSURE WCD is designed to minimize false alarms, with only 6% of patients experiencing one, compared to 46% for the competitor's device.
• The ASSURE WCD delivers a 170 joule shock, compared to the competitor device which delivers a 150 joule shock.
• The ASSURE WCD has a minimum defibrillation capacity of 25 shocks, providing a significant safety buffer for patients experiencing multiple cardiac events within a short time period, such as a VT storm, where a patient experiences multiple episodes of sustained VT within a short period of time.

Related Party Transactions

• Affiliates of Bain Capital have ownership interests in a broad range of companies and may engage in activities where their interests conflict with Kestra's.
• The company has executed one distribution agreement with a DME supplier in order to facilitate billing and collections related to the distribution of our ASSURE WCD.

Stakeholder Impact

• The IPO will provide Kestra with capital to scale its operations and expand its market reach, potentially benefiting shareholders.
• The company's focus on patient comfort and compliance could improve outcomes for cardiac patients.
• The expansion of Kestra's commercial organization will create new job opportunities.
• The company's reliance on third-party suppliers could impact its ability to meet demand for its products.

Next Steps

• The company will continue to scale its commercial operations.
• Kestra will continue to invest in research and development.
• The company will pursue expansion in international markets.
• Kestra will strategically pursue adjacent markets with new product offerings and differentiated services.

Key Dates